Medpace Holdings, Inc. (MEDP) Income Tax Expense
The tax expense for Medpace Holdings, Inc. (MEDP) is $91.25 Million with a year-over-year change of +27.56%. Income tax expense is the amount a company pays in federal, state, and foreign income taxes based on its taxable income for the period.
MEDP Tax Expense Chart
Current Tax Expense
$91.25M
$91.25 Million
Year-over-Year Change
+27.56%
vs. $71.54M prior year
Historical Data
13
Years of data available
Annual Tax Expense History
| Year | Tax Expense | YoY Change | % Change |
|---|---|---|---|
| 2025 | $91.25M | +$19.72M | +27.56% |
| 2024 | $71.54M | +$18.66M | +35.30% |
| 2023 | $52.87M | +$15.38M | +41.02% |
| 2022 | $37.49M | +$17.49M | +87.42% |
| 2021 | $20.00M | $-3.14M | -13.58% |
| 2020 | $23.15M | $-1.24M | -5.09% |
| 2019 | $24.39M | +$3.62M | +17.45% |
| 2018 | $20.77M | +$2.94M | +16.51% |
| 2017 | $17.82M | +$9.29M | +108.90% |
| 2016 | $8.53M | +$7.69M | +912.10% |
| 2015 | $843,000 | +$6.53M | +114.82% |
| 2014 | $-5.69M | $-19.99M | -139.78% |
| 2013 | $14.30M | — | — |
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle